The agreement outlines that BullFrog AI will utilize its advanced artificial intelligence and machine learning capabilities to provide the pharmaceutical client with prioritized drug target candidates, associated causal gene networks, and target dossiers for drug candidates ready for advancement. The agreement is set to remain in effect for one year, during which the company is eligible for milestone payments based on the delivery of specific project deliverables.
Furthermore, the client will have the option to secure exclusive rights to a selected 'final target' drug candidate for research and development purposes for a period of three years. This strategic partnership not only validates BullFrog AI's proprietary capabilities but also positions the company for potential expansion across other areas of the client's research and development portfolio.
Vininder Singh, the CEO of BullFrog AI, expressed confidence in the agreement, stating, "This agreement represents strong, high-quality validation of our proprietary capabilities from a leading industry partner. We look forward to continuing to build on our successful record in identifying and prioritizing portfolios and expanding our commercial partnerships." The agreement is expected to enhance BullFrog AI's operational execution and strategic outlook, potentially leading to increased market presence and revenue growth in the burgeoning field of mental health therapeutics.
